| Bioactivity | Carbazeran (citrate), a potent phosphodiesterase inhibitor, is aldehyde oxidase substrate. Carbazeran (citrate) can be used for the research of metabolic disease[1]. |
| Target | phosphodiesterase |
| In Vivo | Carbazeran (10 mg/kg; p.o.) (citrate) of the unmetabolized in samples from humanized-liver mice, the mean plasma concentrations are lower than in those from control mice for 0.5~4 hours after oral administration[1].Oral administration of carbazeran (citrate) to guinea pigs has reportedly resulted in large kinetic deuterium isotope effects on the AUC and Cmax, without a change of systemic half-life[1]. Animal Model: |
| Name | Carbazeran citrate |
| CAS | 153473-94-0 |
| Formula | C24H32N4O11 |
| Molar Mass | 552.53 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Uehara S, et al. Human Aldehyde Oxidase 1-Mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes. Drug Metab Dispos. 2020;48(7):580-586. |
Carbazeran citrate
CAS: 153473-94-0 F: C24H32N4O11 W: 552.53
Carbazeran (citrate), a potent phosphodiesterase inhibitor, is aldehyde oxidase substrate. Carbazeran (citrate) can be u
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.